The collaboration is designed to test practical ways to connect scientific research directly to clinical workflows and transform care. Initial areas of exploration include clinical trial recruitment, earlier diagnosis, drug-safety monitoring and leveraging real-world evidence across the lifecycle of a medicine, according to the companies. Programmes will span AstraZeneca’s core disease areas including oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare disease.

The first programme will focus on supporting hypertension care and clinical research in Abu Dhabi, in partnership with healthcare company, M42.

The collaboration will span multiple international projects with key regions including the US, Middle East, and Europe working with local governments and within applicable regulations to ensure these could be scaled in the future. The first programme will focus on supporting hypertension care and clinical research in Abu Dhabi, in partnership with healthcare company, M42. This will help clinical teams identify patients with uncontrolled hypertension; implementing guideline-directed care; and improving the recruitment for clinical trials.

“Too many patients are diagnosed late or face a long journey to get the care they need. To build the next decade of medicine, we aim to harness AI to connect learnings across science, clinical trials and everyday care, generating insights that continuously strengthen research, accelerate innovation, and enhance patient outcomes. Bringing together the unique capabilities of Oracle and AstraZeneca, we believe we can support smarter clinical trials, strengthen safety monitoring and help ensure patients are diagnosed sooner and receive the right care,” says Anne-Claire Gerbaldi, Chief Digital, Data and AI Officer, AstraZeneca.

The collaboration will use deidentified real-world data within robust governance, privacy and security arrangements, they state. AstraZeneca will not receive patient-identifiable information. The companies have signed a non-binding term-sheet agreement. No financials are being disclosed as part of this agreement.